Multianalyte detection of cancer biomarkers in human serum using label-free field effect transistor biosensor

Ke Si, Shanshan Cheng, Sho Hideshima, Shigeki Kuroiwa, Takuya Nakanishi, Tetsuya Osaka

Research output: Contribution to journalArticle

Abstract

Recent statistics show that the incidence and mortality of cancer are on the rise. Among all types of cancer, lung cancer and liver cancer are the most prevalent. We have many biomarkers for these two cancers, among which the cytokeratin fragment 21-1 (CYFRA 21-1) and α-fetoprotein (AFP) are the most common and widely used. Among the various detection methods, the field effect transistor (FET) biosensor is one of the most attractive approaches, providing a label-free, fast, and low-cost electrical detection of biomarkers with high specificity and sensitivity. In previous work, we applied biomarkers for a single cancer type. With the detection of CYFRA 21-1 and neuron-specific enolase (NSE), lung cancer was differentiated in the early stages. Compared with the early work, the biomarkers for the two cancer types, CYFRA 21-1 for lung cancer and AFP for liver cancer, were prepared in this work. The detection of CYFRA 21-1 and AFP in human serum was achieved at the same time with the limits of detection of 1 and 10 ng mL−1, while the cut-off values were 4 and 10 ng mL−1. The method featured short analytical time, small sample volume, and low cost. With its good selectivity and appropriate sensitivity, clinical application will become popular in the future.

Original languageEnglish
Pages (from-to)991-999
Number of pages9
JournalSensors and Materials
Volume30
Issue number5
DOIs
Publication statusPublished - 2018 Jan 1
Externally publishedYes

Fingerprint

biomarkers
Biomarkers
Fetal Proteins
Tumor Biomarkers
Keratins
Field effect transistors
bioinstrumentation
Biosensors
serums
Labels
field effect transistors
cancer
Liver
fragments
Phosphopyruvate Hydratase
lungs
Neurons
Costs
liver
Statistics

Keywords

  • Biomarker
  • Concentration-dependent detection
  • Field effect transistor (FET)
  • Multianalyte detection

ASJC Scopus subject areas

  • Instrumentation
  • Materials Science(all)

Cite this

Multianalyte detection of cancer biomarkers in human serum using label-free field effect transistor biosensor. / Si, Ke; Cheng, Shanshan; Hideshima, Sho; Kuroiwa, Shigeki; Nakanishi, Takuya; Osaka, Tetsuya.

In: Sensors and Materials, Vol. 30, No. 5, 01.01.2018, p. 991-999.

Research output: Contribution to journalArticle

@article{7f4e4833e7e64c50bf3c7fc9af1bfd2f,
title = "Multianalyte detection of cancer biomarkers in human serum using label-free field effect transistor biosensor",
abstract = "Recent statistics show that the incidence and mortality of cancer are on the rise. Among all types of cancer, lung cancer and liver cancer are the most prevalent. We have many biomarkers for these two cancers, among which the cytokeratin fragment 21-1 (CYFRA 21-1) and α-fetoprotein (AFP) are the most common and widely used. Among the various detection methods, the field effect transistor (FET) biosensor is one of the most attractive approaches, providing a label-free, fast, and low-cost electrical detection of biomarkers with high specificity and sensitivity. In previous work, we applied biomarkers for a single cancer type. With the detection of CYFRA 21-1 and neuron-specific enolase (NSE), lung cancer was differentiated in the early stages. Compared with the early work, the biomarkers for the two cancer types, CYFRA 21-1 for lung cancer and AFP for liver cancer, were prepared in this work. The detection of CYFRA 21-1 and AFP in human serum was achieved at the same time with the limits of detection of 1 and 10 ng mL−1, while the cut-off values were 4 and 10 ng mL−1. The method featured short analytical time, small sample volume, and low cost. With its good selectivity and appropriate sensitivity, clinical application will become popular in the future.",
keywords = "Biomarker, Concentration-dependent detection, Field effect transistor (FET), Multianalyte detection",
author = "Ke Si and Shanshan Cheng and Sho Hideshima and Shigeki Kuroiwa and Takuya Nakanishi and Tetsuya Osaka",
year = "2018",
month = "1",
day = "1",
doi = "10.18494/SAM.2018.1807",
language = "English",
volume = "30",
pages = "991--999",
journal = "Sensors and Materials",
issn = "0914-4935",
publisher = "M Y U Scientific Publishing Division",
number = "5",

}

TY - JOUR

T1 - Multianalyte detection of cancer biomarkers in human serum using label-free field effect transistor biosensor

AU - Si, Ke

AU - Cheng, Shanshan

AU - Hideshima, Sho

AU - Kuroiwa, Shigeki

AU - Nakanishi, Takuya

AU - Osaka, Tetsuya

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Recent statistics show that the incidence and mortality of cancer are on the rise. Among all types of cancer, lung cancer and liver cancer are the most prevalent. We have many biomarkers for these two cancers, among which the cytokeratin fragment 21-1 (CYFRA 21-1) and α-fetoprotein (AFP) are the most common and widely used. Among the various detection methods, the field effect transistor (FET) biosensor is one of the most attractive approaches, providing a label-free, fast, and low-cost electrical detection of biomarkers with high specificity and sensitivity. In previous work, we applied biomarkers for a single cancer type. With the detection of CYFRA 21-1 and neuron-specific enolase (NSE), lung cancer was differentiated in the early stages. Compared with the early work, the biomarkers for the two cancer types, CYFRA 21-1 for lung cancer and AFP for liver cancer, were prepared in this work. The detection of CYFRA 21-1 and AFP in human serum was achieved at the same time with the limits of detection of 1 and 10 ng mL−1, while the cut-off values were 4 and 10 ng mL−1. The method featured short analytical time, small sample volume, and low cost. With its good selectivity and appropriate sensitivity, clinical application will become popular in the future.

AB - Recent statistics show that the incidence and mortality of cancer are on the rise. Among all types of cancer, lung cancer and liver cancer are the most prevalent. We have many biomarkers for these two cancers, among which the cytokeratin fragment 21-1 (CYFRA 21-1) and α-fetoprotein (AFP) are the most common and widely used. Among the various detection methods, the field effect transistor (FET) biosensor is one of the most attractive approaches, providing a label-free, fast, and low-cost electrical detection of biomarkers with high specificity and sensitivity. In previous work, we applied biomarkers for a single cancer type. With the detection of CYFRA 21-1 and neuron-specific enolase (NSE), lung cancer was differentiated in the early stages. Compared with the early work, the biomarkers for the two cancer types, CYFRA 21-1 for lung cancer and AFP for liver cancer, were prepared in this work. The detection of CYFRA 21-1 and AFP in human serum was achieved at the same time with the limits of detection of 1 and 10 ng mL−1, while the cut-off values were 4 and 10 ng mL−1. The method featured short analytical time, small sample volume, and low cost. With its good selectivity and appropriate sensitivity, clinical application will become popular in the future.

KW - Biomarker

KW - Concentration-dependent detection

KW - Field effect transistor (FET)

KW - Multianalyte detection

UR - http://www.scopus.com/inward/record.url?scp=85047124017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047124017&partnerID=8YFLogxK

U2 - 10.18494/SAM.2018.1807

DO - 10.18494/SAM.2018.1807

M3 - Article

VL - 30

SP - 991

EP - 999

JO - Sensors and Materials

JF - Sensors and Materials

SN - 0914-4935

IS - 5

ER -